Financial Performance - The company's operating revenue for 2020 was ¥614,894,440.85, a decrease of 14.41% compared to ¥718,384,535.71 in 2019[27]. - The net profit attributable to shareholders for 2020 was ¥272,264,655.97, down 20.79% from ¥343,706,532.78 in 2019[27]. - The net profit after deducting non-recurring gains and losses was ¥224,528,311.79, a decline of 31.85% from ¥329,475,838.43 in 2019[27]. - The net cash flow from operating activities increased by 13.65% to ¥416,571,982.43 in 2020, compared to ¥366,536,248.37 in 2019[27]. - The total assets at the end of 2020 were ¥3,425,191,470.28, reflecting a 64.70% increase from ¥2,079,607,778.24 at the end of 2019[27]. - The net assets attributable to shareholders at the end of 2020 were ¥2,909,810,863.34, up 66.94% from ¥1,743,033,011.20 at the end of 2019[27]. - The basic earnings per share for 2020 was ¥0.54, a decrease of 25.00% from ¥0.72 in 2019[27]. - The diluted earnings per share for 2020 was also ¥0.54, down 25.00% from ¥0.72 in 2019[27]. - The company reported a government subsidy of ¥49,274,004.09 in 2020, significantly higher than ¥6,128,657.79 in 2019[33]. - In 2020, the company achieved operating revenue of 614.89 million yuan, a decrease of 14.41% compared to the previous year[55]. - The net profit attributable to shareholders was 272.26 million yuan, down 20.79% year-on-year[55]. Investment and Projects - The company is investing in the Jinxi Technology Park project, which is expected to enhance its strategic development and operational scale, although there are uncertainties regarding construction progress and costs[6]. - The company acknowledges the risks associated with project investments, including potential changes in engineering quality and investment costs[6]. - The company has committed to invest CNY 12,550 million in the core premix project, with a cumulative investment of CNY 77.72 million by the end of the reporting period[88]. - The annual production project of 4,000 tons of environmentally friendly rodenticide has a total investment commitment of CNY 15,500 million, with CNY 2,091.9 million invested to date[88]. - The annual production of 180 tons of 7-dehydrocholesterol project has an adjusted total investment of CNY 8,000 million, with a cumulative investment of CNY 9,144.67 million, achieving 114.31% of the investment progress[88]. - The company plans to relocate its production base to Jinhua Economic and Technological Development Zone to improve operational efficiency and reduce costs[94]. - The company has approved the replacement of self-raised funds with raised funds for several projects, totaling CNY 215,944.55 million[95]. Talent and Human Resources - The company faces a substantial increase in demand for high-quality talent in R&D, production, sales, and management, necessitating significant investments in human capital[7]. - The company has implemented a talent strategy focused on employee development and compliance with labor laws[166]. Market Strategy and Product Development - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[6]. - The company aims to enhance its market position in the vitamin D3 sector by integrating production and market strategies, targeting a steady increase in market prices[107]. - The company has completed the layout of the entire vitamin D3 industry chain, focusing on innovation and market expansion[106]. - The company has established a clear full industry chain advantage, integrating upstream and downstream operations in the vitamin D3 sector[47]. - The company has a leading production technology advantage, with its processes for vitamin D3 and NF-grade cholesterol being at the forefront of the industry[48]. Shareholder and Dividend Information - The profit distribution plan approved by the board proposes a cash dividend of 1.03 CNY per 10 shares, based on a total of 543,332,767 shares[10]. - The company’s cash dividend distribution policy aligns with its articles of association and shareholder resolutions, ensuring transparency and compliance[111]. - The company has committed to distributing cash dividends if there are no major investment plans or significant cash expenditures, ensuring that the cash dividends will not be less than the distributable profits for the year[120]. - The company’s cash dividends for 2020 were 20.55% of the net profit attributable to ordinary shareholders, with a total cash dividend of RMB 55,963,275.00[116]. - The company’s cash dividend distribution in 2019 was 29.10% of the net profit attributable to ordinary shareholders, with a total cash dividend of RMB 100,001,821.18[116]. Governance and Compliance - The company is committed to ensuring the accuracy and completeness of its financial reports, with all board members present for the review[6]. - The company has established a robust governance structure to manage risks related to human resources and project investments[6]. - The company has established measures to ensure the fulfillment of public commitments by its controlling shareholders and management, including penalties for non-compliance[123]. - The company has committed to repurchasing shares if there are false records or misleading statements in the prospectus, ensuring compliance with regulatory requirements[120]. Cash Flow and Financing - The cash flow from operating activities was CNY 416.57 million, an increase of 13.65% year-on-year, mainly due to higher government subsidies and tax refunds[60]. - The company completed a private placement raising CNY 909.4 million, which will be used for expanding production capacity in various projects[56]. - The company’s cash and cash equivalents at the end of 2020 were CNY 1.16 billion, a 129.10% increase from the beginning of the year[60]. - The company’s cash flow from financing activities increased by 861.69% to ¥831,740,316.69, primarily due to a non-public offering of 71,719,242 shares, raising ¥909,399,988.56[79]. Customer and Supplier Concentration - Total sales from the top five customers amounted to ¥303,518,707.95, accounting for 49.35% of the annual total sales[70]. - The largest customer contributed ¥142,221,670.34, representing 23.13% of the annual total sales[70]. - Total purchases from the top five suppliers reached ¥131,930,683.62, which is 57.41% of the annual total purchases[73]. - The largest supplier accounted for ¥44,491,980.00, or 19.36% of the annual total purchases[73].
花园生物(300401) - 2020 Q4 - 年度财报